Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 14;12(2):432.
doi: 10.3390/biomedicines12020432.

Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments

Andrea Mormone  1 , Giovanni Tortorella  1 , Francesca Esposito  1 , Alfredo Caturano  1   2 , Aldo Marrone  1 , Domenico Cozzolino  1 , Raffaele Galiero  1 , Raffaele Marfella  1 , Ferdinando Carlo Sasso  1 , Luca Rinaldi  3
Affiliations
Review

Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments

Andrea Mormone et al. Biomedicines. .

Abstract

Hypercholesterolemia plays a crucial role in the formation of lipid plaques, particularly with elevated low-density lipoprotein (LDL-C) levels, which are linked to increased risks of cardiovascular disease, cerebrovascular disease, and peripheral arterial disease. Controlling blood cholesterol values, specifically reducing LDL-C, is widely recognized as a key modifiable risk factor for decreasing the morbidity and mortality associated with cardiovascular diseases. Historically, statins, by inhibiting the enzyme β-hydroxy β-methylglutaryl-coenzyme A (HMG)-CoA reductase, have been among the most effective drugs. However, newer non-statin agents have since been introduced into hypercholesterolemia therapy, providing a viable alternative with a favorable cost-benefit ratio. This paper aims to delve into the latest therapies, shedding light on their mechanisms of action and therapeutic benefits.

Keywords: atherosclerosis; cardiovascular disease; hypercholesterolemia; lipid-lowering drugs; statins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart.
Figure 2
Figure 2
The mechanisms of the main cholesterol-lowering drugs.
See this image and copyright information in PMC

References

    1. Libby P., Sukhova G., Lee R.T., Liao J.K. Molecular biology of atherosclerosis. Int. J. Cardiol. 1997;62:S23–S29. doi: 10.1016/S0167-5273(97)00238-6. - DOI - PubMed
    1. Kumric M., Borovac J.A., Martinovic D., Kurir T.T., Bozic J. Circulating Biomarkers Reflecting Destabilization Mechanisms of Coronary Artery Plaques: Are We Looking for the Impossible? Biomolecules. 2021;11:881. doi: 10.3390/biom11060881. - DOI - PMC - PubMed
    1. Yurdagul A., Finney A.C., Woolard M.D., Orr A.W. The arterial microenvironment: The where and why of atherosclerosis. Biochem. J. 2016;473:1281–1295. doi: 10.1042/BJ20150844. - DOI - PMC - PubMed
    1. Sasso F.C., Simeon V., Galiero R., Caturano A., De Nicola L., Chiodini P., Rinaldi L., Salvatore T., Lettieri M., Nevola R., et al. The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial. Cardiovasc. Diabetol. 2022;21:235. doi: 10.1186/s12933-022-01674-7. - DOI - PMC - PubMed
    1. Caturano A., D’Angelo M., Mormone A., Russo V., Mollica M.P., Salvatore T., Galiero R., Rinaldi L., Vetrano E., Marfella R., et al. Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications. Curr. Issues Mol. Biol. 2023;45:6651–6666. doi: 10.3390/cimb45080420. - DOI - PMC - PubMed

LinkOut - more resources